PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the effect of GnRH agonist (GnRH-a) down-regulation prior to hormone replacement treatment (HRT) to prepare the endometrium in frozen embryo transfer (FET) cycles in women of different ages.
UNASSIGNED: This was a retrospective study, and after excluding patients with adenomyosis, endometriosis, severe endometrial adhesions, polycystic ovary syndrome (PCOS), and repeated embryo implantation failures, a total of 4,091 HRT cycles were collected. Patients were divided into group A (<35 years old) and group B (≥35 years old), and each group was further divided into HRT and GnRHa-HRT groups. The clinical outcomes were compared between groups.
UNASSIGNED: There was no statistically significant difference in clinical outcomes between the HRT and GnRHa-HRT groups among women aged <35 years. In women of advanced age, higher rates of clinical pregnancy and live birth were seen in the GnRHa-HRT group. Logistic regression analysis showed that female age and number of embryos transferred influenced the live birth rate in FET cycles, and in women aged ≥ 35 years, the use of GnRH-a down-regulation prior to HRT improved pregnancy outcomes.
UNASSIGNED: In elderly woman without adenomyosis, endometriosis, PCOS, severe uterine adhesions, and RIF, hormone replacement treatment with GnRH agonist for pituitary suppression can improve the live birth rate of FET cycles.
UNASSIGNED: This was a retrospective study, and after excluding patients with adenomyosis, endometriosis, severe endometrial adhesions, polycystic ovary syndrome (PCOS), and repeated embryo implantation failures, a total of 4,091 HRT cycles were collected. Patients were divided into group A (<35 years old) and group B (≥35 years old), and each group was further divided into HRT and GnRHa-HRT groups. The clinical outcomes were compared between groups.
UNASSIGNED: There was no statistically significant difference in clinical outcomes between the HRT and GnRHa-HRT groups among women aged <35 years. In women of advanced age, higher rates of clinical pregnancy and live birth were seen in the GnRHa-HRT group. Logistic regression analysis showed that female age and number of embryos transferred influenced the live birth rate in FET cycles, and in women aged ≥ 35 years, the use of GnRH-a down-regulation prior to HRT improved pregnancy outcomes.
UNASSIGNED: In elderly woman without adenomyosis, endometriosis, PCOS, severe uterine adhesions, and RIF, hormone replacement treatment with GnRH agonist for pituitary suppression can improve the live birth rate of FET cycles.
摘要：
■研究不同年龄女性在冷冻胚胎移植（FET）周期中激素替代治疗（HRT）前GnRH激动剂（GnRH-a）下调准备子宫内膜的作用。
■这是一项回顾性研究，排除子宫腺肌病患者后，子宫内膜异位症,严重的子宫内膜粘连，多囊卵巢综合征（PCOS），反复的胚胎植入失败，共收集4,091个HRT周期。将患者分为A组（<35岁）和B组（≥35岁），每组再分为HRT和GnRHa-HRT组。比较两组的临床疗效。
■在年龄<35岁的女性中，HRT组和GnRHa-HRT组的临床结果无统计学差异。在高龄女性中，GnRHa-HRT组的临床妊娠率和活产率较高.Logistic回归分析显示，女性年龄和胚胎移植数量影响FET周期活产率，在35岁以上的女性中，在HRT前使用GnRH-a下调可改善妊娠结局.
■在没有子宫腺肌病的老年女性中，子宫内膜异位症,PCOS,严重的宫腔粘连,RIF,GnRH激动剂用于垂体抑制的激素替代治疗可以提高FET周期的活产率。
■这是一项回顾性研究，排除子宫腺肌病患者后，子宫内膜异位症,严重的子宫内膜粘连，多囊卵巢综合征（PCOS），反复的胚胎植入失败，共收集4,091个HRT周期。将患者分为A组（<35岁）和B组（≥35岁），每组再分为HRT和GnRHa-HRT组。比较两组的临床疗效。
■在年龄<35岁的女性中，HRT组和GnRHa-HRT组的临床结果无统计学差异。在高龄女性中，GnRHa-HRT组的临床妊娠率和活产率较高.Logistic回归分析显示，女性年龄和胚胎移植数量影响FET周期活产率，在35岁以上的女性中，在HRT前使用GnRH-a下调可改善妊娠结局.
■在没有子宫腺肌病的老年女性中，子宫内膜异位症,PCOS,严重的宫腔粘连,RIF,GnRH激动剂用于垂体抑制的激素替代治疗可以提高FET周期的活产率。
